Sprint Bioscience Q4 2023: A major step towards break-even - Redeye

Sprint Bioscience recorded sales improved to SEK 10.9m from SEK 0.3m (Q4 2022), and operating cash flow improved by SEK -12.5m to a cash burn of SEK -2.7m. The main difference is the support from recurring services related to VADA and the VRK1 program. Spring BioScience can also negotiate with new potential partners for the DISA, NIMA and NASH programs. We adjust our base case to SEK 2.9 (SEK 3.2).

Länk till analysen i sin helhet: https://www.redeye.se/research/979531/sprint-bioscience-q4-2023-a-major-step-towards-break-even?utm_source=finwire&utm_medium=RSS